Trocoxil

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

mavacoxib

Available from:

Zoetis Belgium SA

ATC code:

QM01AH92

INN (International Name):

mavacoxib

Therapeutic group:

Klieb

Therapeutic area:

Anti-infjammatorji u anti-rewmatiċi-prodotti

Therapeutic indications:

Għat-trattament ta 'uġigħ u infjammazzjoni assoċjati ma' mard konġunt deġenerattiv fil-klieb f'każijiet fejn ikun indikat trattament kontinwu ta 'iktar minn xahar.

Product summary:

Revision: 10

Authorization status:

Awtorizzat

Authorization date:

2008-09-09

Patient Information leaflet

                                15
B. FULJETT TA’ TAGĦRIF
16
FULJETT TA’ TAGĦRIF GĦAL:
TROCOXIL 6MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
TROCOXIL 20MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
TROCOXIL 30MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
TROCOXIL 75MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
TROCOXIL 95MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
IL-BELĠJU
Manifattur responsabbli għall-ħrug tal-lott
:
Pfizer Italia s.r.l.
Località Marino del Tronto
63100 Ascoli Piceno (AP)
L-ITALJA
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Trocoxil 6mg pilloli li jintmagħdu għal klieb
Trocoxil 20mg pilloli li jintmagħdu għal klieb
Trocoxil 30mg pilloli li jintmagħdu għal klieb
Trocoxil 75mg pilloli li jintmagħdu għal klieb
Trocoxil 95mg pilloli li jintmagħdu għal klieb
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
SUSTANZA ATTIVA:
Mavacoxib
6 mg
Mavacoxib
20 mg
Mavacoxib
30 mg.
Mavacoxib
75 mg
Mavacoxib
95 mg
Il-pilloli fihom ukoll dawn l-ingredjenti (mhux attivi)
Zokkor
Silicified microcrystalline cellulose
Trab artifiċjali li jagħti togħma ta’ċanga
Croscarmellose sodium
Sodium laurylsulfate
Magnesium stearate
Pillola triangulari b’dehra kannella mtabba’ bis-saħħa
tal-pillola bbuzzata fuq naħa, u n-naħa l-oħra
m’hemm xejn.
17
4 .
INDIKAZZJONI(JIET)
Trocoxil® pilloli li jintmagħdu huma indikati għall-kura ta’
uġiegħ u infjammazzjoni assoċjati ma’
mard diġenerattiv tal-ġogi fil-klieb meta tkun meħtieġa kura għal
aktar minn xahar.
Trocoxil tagħmel parti mill-grupp ta’ mediċini li jissejħu
Non-steroidal Anti-inflammatory drugs
(NSAIDs) li jintużaw għal kura ta’uġiegħ u infjammazzjoni.
5 .
KONTRAINDIKAZZJONIJIET
Tużax fi klieb ta’ anqas minn 12-il xahar fl-età u/jew ta’ anqas
minn 5kg piż tal-ġise
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Trocoxil 6mg pilloli li jintmagħdugħal klieb
Trocoxil 20mg pilloli li jintmagħdu għal klieb
Trocoxil 30mg pilloli li jintmagħdu għal klieb
Trocoxil 75mg pilloli li jintmagħdu għal klieb
Trocoxil 95mg pilloli li jintmagħdu għal klieb
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull pillola li tintmagħad fiha:
SUSTANZA ATTIVA:
Mavacoxib
6 mg
Mavacoxib
20 mg
Mavacoxib
30 mg
Mavacoxib
75 mg
Mavacoxib
95 mg
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pilloli li jintmagħdu.
Pillola triangulari b’dehra kannella mtabba’ bis-saħħa
tal-pillola bbuzzata fuq naħa, u n-naħa l-oħra
m’hemm xejn.
4
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb minn 12-il xhar ’il fuq.
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Għall-kura ta’ uġiegħ u infjammazzjoni assoċjati ma’ mard
diġenerattiv tal-ġogi fil-klieb, f’każijiet
fejn huwa indikat trattament kontinwu għal aktar minn xahar.
4.3
KONTRA INDIKAZZJONIJIET
Tużax fi klieb ta’ anqas minn 12-il xahar fl-età u/jew li jiżnu
anqas minn 5kg.
Tużax fi klieb li jsofru minn diżordnijiet gastro-intestinali li
jinkludu ulċeri u telf ta’ demm.
Tużax meta jkun hemm sinjali ta’ diżordnijiet emorraġiċi.
Tużax f’każijiet fejn il-kliewi jew il-fwied mhumiex
f’saħħithom.
Tużax f’każi ta’ insuffiċjenza kardijaka
Tużax fi kliebtqal, tat-tagħmmir jew li qed ireddgħu.
Tużax f'każijiet ta’sensittività għall-ingredjent attiv,
ingredjenti mhux attivi jew ingredjenti oħra.
Tużax f'każ ta’ sensittività magħrufa għas-sulfonamidi.
Tużax fl-istess ħin ma’ glukokortikosterojdi jew
_Non-Steroidal Anti-Inflammatory Drugs _
(NSAIDs)
oħra, ara sezzjoni 4.8.
Evita l-użu f’kull annimal diżidrat, b’volum baxx ta’ demm jew
bi pressjoni baxxa, billi hemm riskju
ta’ żieda fit-tossiċità tas-sistema 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 06-11-2018
Public Assessment Report Public Assessment Report Bulgarian 21-07-2013
Patient Information leaflet Patient Information leaflet Spanish 05-05-2020
Public Assessment Report Public Assessment Report Spanish 21-07-2013
Patient Information leaflet Patient Information leaflet Czech 06-11-2018
Public Assessment Report Public Assessment Report Czech 21-07-2013
Patient Information leaflet Patient Information leaflet Danish 05-05-2020
Public Assessment Report Public Assessment Report Danish 21-07-2013
Patient Information leaflet Patient Information leaflet German 05-05-2020
Public Assessment Report Public Assessment Report German 21-07-2013
Patient Information leaflet Patient Information leaflet Estonian 05-05-2020
Public Assessment Report Public Assessment Report Estonian 21-07-2013
Patient Information leaflet Patient Information leaflet Greek 05-05-2020
Public Assessment Report Public Assessment Report Greek 21-07-2013
Patient Information leaflet Patient Information leaflet English 05-05-2020
Public Assessment Report Public Assessment Report English 21-07-2013
Patient Information leaflet Patient Information leaflet French 05-05-2020
Public Assessment Report Public Assessment Report French 21-07-2013
Patient Information leaflet Patient Information leaflet Italian 05-05-2020
Public Assessment Report Public Assessment Report Italian 21-07-2013
Patient Information leaflet Patient Information leaflet Latvian 05-05-2020
Public Assessment Report Public Assessment Report Latvian 21-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 05-05-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-05-2020
Public Assessment Report Public Assessment Report Lithuanian 21-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 05-05-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 05-05-2020
Public Assessment Report Public Assessment Report Hungarian 21-07-2013
Patient Information leaflet Patient Information leaflet Dutch 05-05-2020
Public Assessment Report Public Assessment Report Dutch 21-07-2013
Patient Information leaflet Patient Information leaflet Polish 05-05-2020
Public Assessment Report Public Assessment Report Polish 21-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 05-05-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 05-05-2020
Public Assessment Report Public Assessment Report Portuguese 21-07-2013
Patient Information leaflet Patient Information leaflet Romanian 05-05-2020
Public Assessment Report Public Assessment Report Romanian 21-07-2013
Patient Information leaflet Patient Information leaflet Slovak 05-05-2020
Public Assessment Report Public Assessment Report Slovak 21-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 05-05-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 05-05-2020
Public Assessment Report Public Assessment Report Slovenian 21-07-2013
Patient Information leaflet Patient Information leaflet Finnish 05-05-2020
Public Assessment Report Public Assessment Report Finnish 21-07-2013
Patient Information leaflet Patient Information leaflet Swedish 05-05-2020
Public Assessment Report Public Assessment Report Swedish 21-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 05-05-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 05-05-2020
Patient Information leaflet Patient Information leaflet Icelandic 05-05-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 05-05-2020
Patient Information leaflet Patient Information leaflet Croatian 05-05-2020

Search alerts related to this product

View documents history